Roche plans to suspend its HIV research because pending medicines fail to show significant improvement over existing therapies, according to a company statement. The company also claimed it will “refocus resources within virology on diseases in which the company can deliver substantial improvements over existing medications.” Research scientists currently working in HIV will be reassigned to other activities, according to Linda Dyson, a spokeswoman in Roche’s U.S. office in NJ....